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Abstract
Introduction CCN6/WISP3 belongs to the CCN (Cyr61,
CTGF, Nov) family of genes that contains a conserved insulin-
like growth factor (IGF) binding protein motif. CCN6 is a
secreted protein lost in 80% of the aggressive inflammatory
breast cancers, and can decrease mammary tumor growth in
vitro and in vivo. We hypothesized that inhibition of CCN6 might
result in the loss of a growth regulatory function that protects
mammary epithelial cells from the tumorigenic effects of growth
factors, particularly IGF-1.
Method We treated human mammary epithelial (HME) cells with
a CCN6 hairpin short interfering RNA.
Results CCN6-deficient cells showed increased motility and
invasiveness, and developed features of epithelial-mesenchymal
transition (EMT). Inhibition of CCN6 expression promoted
anchorage-independent growth of HME cells and rendered
them more responsive to the growth effects of IGF-1, which was
coupled with the increased phosphorylation of IGF-1 receptor
and insulin receptor substrate-1 (IRS-1).
Conclusion Specific stable inhibition of CCN6 expression in
HME cells induces EMT, promotes anchorage-independent
growth, motility and invasiveness, and sensitizes mammary
epithelial cells to the growth effects of IGF-1.
Introduction
Wnt-1-induced secreted protein 3 (CCN6/WISP3) is a
cysteine-rich protein that belongs to the CCN (Cyr61, CTGF,
Nov) family of genes, which also contains five other members:
CCN1 (connective tissue growth factor or CTGF), CCN2
(Cyr61), CCN3 (Nov), CCN4 (WISP1) and CCN5 (WISP2)
[1-3]. CCN4, the first cloned member of the WISP proteins
was discovered because it was upregulated in the mouse
mammary epithelial cell line C57MG transformed by Wnt-1
[2]. CCN6 shares high sequence homology to CCN4,
although there is no evidence that CCN6 is induced by Wnt-
1 signaling [2]. CCN growth factors are mostly secreted and
extracellular matrix-associated proteins that regulate important
functions including cellular differentiation and development,
cell proliferation, survival, angiogenesis, cell migration and
adhesion [2-6]. CCN proteins interact with key signaling mol-
ecules such as cell surface integrins, NOTCH1, fibulin C,
S100A4, and ion channels [7-12].
CCN proteins contain an N-terminal secretory signal, followed
by four distinct motifs with homology to insulin-like growth fac-
tor (IGF)-binding protein; von Willebrand factor type C; throm-
bospondin 1 (TSP1); and a C-terminal region with heparin-
binding motifs and sequence similarities to the C termini of von
Willebrand factor and mucins, the latter also being present in
other growth factors such as transforming growth factor-β,
platelet-derived growth factor, and nerve growth factor [1,2,9].
It is becoming increasingly evident that CCN proteins function
in a cell-type-specific and tissue-type-specific manner. For
example, increased expression of CCN3 (Nov) was correlated
bp = base pair; EGF = epidermal growth factor; EMT = epithelial-mesenchymal transition; FBS = fetal bovine serum; HME = human mammary epi-
thelial; IGF = insulin-like growth factor; IGF-1R = insulin-like growth factor-1 receptor; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium 
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with reduced tumorigenicity in glioma, choriocarcinoma, and
Ewing's sarcoma cell lines [13-16]. However, increased
expression of CCN3 was associated with enhanced tumor
growth in renal cell carcinomas [17]. CCN2 (Cyr61) stimu-
lates the growth of breast and gastric adenocarcinomas
[18,19], whereas its expression is downregulated in non-small
cell lung cancer, in which CCN2 suppressed the growth of
NSCLC cells by triggering a signal transduction pathway
through β-catenin [20,21]. These data suggest that two mem-
bers of the CCN family, CCN2 and CCN3, behave under cer-
tain circumstances as oncogenes or tumor suppressor genes
in different tissue types (reviewed in [12,22]).
CCN6 maps to chromosome 6q21-22, a locus that displays
high rates of loss of heterozygosity in breast cancer [23,24].
We have previously reported that CCN6 is lost in the majority
of inflammatory breast cancers, a highly aggressive and meta-
static form of breast cancer [25]. Restoration of CCN6 expres-
sion in inflammatory breast cancer cells results in growth
inhibition in vitro and in vivo [6,26]. After synthesis, CCN6
protein is secreted and is able to modulate the effects of IGF-
1 on IGF-1 receptor (IGF-1R) activation and its signaling path-
ways [27]. Here we investigate the function of CCN6 in the
normal breast epithelium. We show that inhibition of CCN6
expression in human mammary epithelial cells strongly induces
epithelial-mesenchymal transition (EMT) and leads to a highly
motile and invasive phenotype. CCN6 loss promotes anchor-
age-independent growth in breast epithelial cells and
increases cell proliferation, which is mechanistically driven, at
least in part, by enhancement of the growth effects of IGF-1
and the activation of IGF-1R signaling pathways.
Materials and methods
Cell culture
Human mammary epithelial (HME) cells were immortalized
with human papilloma virus E6/E7 and were characterized as
being positive for keratin 19 [6,28]. Cells were cultured in
Ham's F-12 medium supplemented with 5% fetal bovine
serum (FBS), hydrocortisone (1 µg/ml), insulin (5 µg/ml), epi-
dermal growth factor (EGF; 10 ng/ml), cholera toxin (100 µg/
ml), fungizone (2.5 µg/ml) and gentamycin (5 µg/ml), at 37°C
under 10% CO2.
Generation of stable hairpin short interfering RNA-CCN6 
HME cells
Hairpin short interfering RNA (siRNA) 5'-
GATCCCGCCAGGGGAAATCTGCAATGTTCAAGAGA-
CATTGCAGATTTCCCCTGGTTTTTTGGAAA-3' and the
complementary strand 5'-AGCTTTTCCAAAAAACCAG-
GGGAAATCTGCAATGTCTCTTGAACATTGCAGATTTC-
CCCTGGCGG-3' were synthesized (Invitrogen, Carlsbad,
CA, USA), and annealed hairpin siRNA-CCN6 inserts were
cloned into pSilencer2.1-U6 hygro expression vector (Ambion,
Austin, TX, USA). The sequence of siRNA-CCN6 (insert in)
expression vector was confirmed by sequencing (University of
Michigan DNA Sequencing Core). HME cells were trans-
fected with pSilencer2.1-U6 negative control (siRNA-control;
Ambion) or siRNA-CCN6 plasmids by using FuGene 6 trans-
fection reagent (Roche-Boehringer Mannheim, Mannheim,
Germany). Stable transfectants were established by culturing
transfected cells in the described medium supplemented with
100 µg/ml hygromycin (Invitrogen) for 4 weeks.
RT-PCR analysis
Total RNA was isolated from HME cells and siRNA HME
clones with a Trizol kit (Life Technologies, Inc., Gaithersburg,
MD, USA). First-strand cDNA synthesis was performed by
using 1 µg of total RNA with AMV reverse transcriptase
(Promega, Madison, WI, USA) and oligo(dT) as a primer. A 2
µl portion of the reaction mixture was used for amplification by
PCR. The following primers were used: CCN6 forward primer
5'-ATGCAGGGGCTCCTCTTCTCC-3' and CCN6 reverse
primer 5'-CTTGAGCTCAGAAAATATATC-3' to amplify a
1,050 bp product; E-cadherin forward primer 5'-CCTTCCTC-
CCAATACATCTCCC-3' and E-cadherin reverse primer 5'-
TCTCCGCCTCCTTCTTCATC-3' to amplify a 600 bp prod-
uct. PCR was performed under the following conditions: dena-
turing for 1 minute at 94°C, annealing for 1 minute at 58°C for
CCN6 and at 65°C for E-cadherin, and elongation for 1 minute
at 72°C, for 35 cycles.
Immunofluorescence
Cells were grown on glass coverslips, fixed with methanol for
5 minutes at -20°C and then permeabilized with 0.2% Triton
X-100 for 15 minutes at room temperature 25°C. The cover-
slips were then saturated for 30 minutes with 2% bovine
serum albumin in PBS. After being washed in PBS, cells were
incubated for 1 hour with a monoclonal antibody against E-
cadherin (dilution 1:50, BD Transduction Laboratories, San
Jose, CA, USA). Cells were exposed for 1 hour to Alexa Fluor
anti-mouse Ig G (Molecular Probes, Eugene, OR, USA). After
being washed with PBS three times, the coverslips were then
mounted with prolong Gold anti-fade reagent with 4',6-diamid-
ino-2-phenylindole and the borders were sealed with transpar-
ent nail polish.
Anchorage-independent growth
For studies of anchorage-independent growth we performed
soft agar assays on stable clones of HME/CCN6 siRNA and
on HME control cells. Each well of a six-well plate was first lay-
ered with 0.6% agar diluted with 5% FBS-supplemented
Ham's F-12 medium complete with growth factors. The cell
layer was then prepared by diluting agarose to concentrations
of 0.3% with 5 × 103 cells in 2.5% FBS-supplemented Ham's
F-12 (1.5 ml per well). Plates were maintained for 3 weeks at
37°C under 10% CO2. Colonies were counted under a micro-
scope with a grid. The experiment was performed three times
independently.Available online http://breast-cancer-research.com/content/7/6/R1080
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Figure 1
Effect of CCN6 inhibition on the phenotype of mammary epithelial cells Effect of CCN6 inhibition on the phenotype of mammary epithelial cells. (a) Human mammary epithelial (HME) cells were stably transfected with 
pSilencer2.1-U6 hygro expression vector expressing CCN6 hairpin siRNA. The suppression of CCN6 was confirmed by reverse transcriptase PCR 
and Western immunoblotting (WB). HME control cells express low levels of CCN6 protein. C1 and C2 (two stable HME CCN6 siRNA clones) show 
almost complete inhibition of CCN6. (b) Stable inhibition of CCN6 on HME cells results in a change from compact and oval-shaped cells to irregu-
larly shaped cells with many protruding processes. (c) E-cadherin protein and mRNA were decreased in CCN6-deficient cells. (d) By immunofluo-
rescence CCN6-deficient cells show a drastic decrease of membrane-associated E-cadherin protein. (e) Western immunoblots show that CCN6 
inhibition results in a decrease in cytokeratin and an increase in vimentin proteins. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.Breast Cancer Research    Vol 7 No 6    Zhang et al.
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Basement membrane matrix invasion
HME/CCN6 siRNA and HME controls were trypsinized and
300 µl of 106 cells/ml in serum-free medium were seeded at
equal numbers onto the extracellular matrix layer (ECM;
Chemicon, Temecula, CA, USA). Subsequently, we added
500 µl of medium containing 5% FBS to the lower chamber.
After incubation for 24 hours, the non-invading cells and ECM
gel from the interior of the insert were removed gently with a
cotton swab. The invasive cells on the lower surface of mem-
brane were stained, air dried, and photographed. The invaded
cells were counted under the microscope. The experiment
was performed three times independently.
Random motility
Random cell motility was determined as described in the motil-
ity assay kit (Cellomics Inc., Pittsburg, PA, USA). Cells were
harvested and 500 cells per well were suspended in 2.5%
FBS medium and plated on top of a field of microscopic fluo-
rescent beads in a 96-well plate. After incubation for 16 hours,
cells were fixed and areas of clearing in the fluorescent bead
field corresponding to phagokinetic cell tracks were quantified
with an NIH ScionImager. The experiment was performed
three times independently.
Immunoprecipitation
HME cells and HME/CCN6 siRNA cells were serum-starved
for 24 hours and subsequently stimulated for 15 minutes with
25 ng/ml IGF-1. Proteins were obtained by lysing the cells in
Figure 2
Effect of CCN6 inhibition on random motility and invasion Effect of CCN6 inhibition on random motility and invasion. (a) A reconstituted basement membrane invasion chamber assay was used to investigate 
the effects of CCN6 inhibition on the invasion abilities of HME cells. Representative fields of invaded and stained cells are shown. t test *p < 0.04 vs. 
control. (b) Cell motility on a field of microscopic fluorescent beads. Representative photomicrographs show the clearing in the fluorescent bead 
field corresponding to phagokinetic cell tracks. *p < 0.005 vs. control. Experiments were performed independently three times. C1 and C2 are two 
stable CCN6 deficient clones.
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a buffer composed of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
1% Nonidet P40, 1 mM Na3VO4, 1 mM phenylmethylsulphonyl
fluoride, 1 µg/ml leupeptin, and 10 µg/ml aprotinin. The IGF-
1R was immunoprecipitated overnight from 500 µg of cell
(protein) lysate with anti-IGF-1R monoclonal antibody (Onco-
gene, San Diego, CA, USA) at 4°C. After isolation with protein
A/G PLUS-Agarose (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), the immunocomplexes were separated by 7.5%
SDS-PAGE. The proteins were transferred to a poly(vinylidene
difluoride) membrane and subsequently detected by immuno-
blotting with anti-IGF-1R β subunit polyclonal antibody (Santa
Cruz Biotechnology). Tyrosine phosphorylation of immunopre-
cipitated IGF-1R was assessed with anti-phosphotyrosine
monoclonal antibody PY20 (Transduction Laboratories, Lex-
ington, KY, USA).
Western blot analysis
Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150
mM NaCl, 1% Nonidet P40, 1 mM Na3VO4, 1 mM phenylmeth-
ylsulphonyl fluoride, 1 µg/ml leupeptin, and 10 µg/ml apro-
tinin). Cell lysates (50 µg of protein) were fractionated by
SDS-PAGE and transferred to Immobilon-P membrane (Milli-
pore, Billerica, MA, USA). The membranes were blocked for 1
hour with Tris-buffered saline containing 5% non-fat milk and
0.1% Tween 20. Immobilized proteins were probed with anti-
bodies specific for phosphorylated and total insulin receptor
substrate-1 (IRS-1; Upstate Biotechnology), E-cadherin and
vimentin monoclonal antibodies (BD Transduction Laborato-
ries) and antibodies against cytokeratin 18 (c-04, ab668,
Abcam Inc, Cambridge MA, USA). CCN6 was detected with
a polyclonal anti-CCN6 antibody developed against an immu-
nogenic peptide Ac-PEGRPGEVSDAPQRKQ-CONH2 corre-
sponding to amino acids 31 to 46 of human CCN6 with the
assistance of Covance.
IGF-1 growth assay
HME/CCN6 siRNA and HME control cells were plated in 96-
well plates at a concentration of 5 × 104 cells/ml and serum-
starved for 24 hours. Subsequently, 25 ng/ml human recom-
binant IGF-1 (Upstate Biotechnology) was added. 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) reagents were added 24 hours later in accordance with
the manufacturer's protocol, and the plate was read at a wave-
length of 595 nm. The experiment was performed with tripli-
cate samples.
S-phase analysis
HME/CCN6 siRNA and HME control cells were plated at a
concentration of 5 × 104 cells/ml and serum-starved for 24
hours. Subsequently, 25 ng/ml human recombinant IGF-1
(Upstate Biotechnology) was added. Serum-starved and IGF-
1-treated HME control cells and HME/CCN6 siRNA cells
were pulsed for 2 hours with 10 µM bromodeoxyuridine
(BrdU; Roche, Indianapolis, IN, USA), harvested with trypsin-
EDTA, and fixed with 70% ethanol at -20°C for at least 1 hour.
Figure 3
CCN6-deficient cells acquire anchorage-independent growth abilities CCN6-deficient cells acquire anchorage-independent growth abilities. 
(a) Anchorage-independent growth of human mammary epithelial sta-
ble cell lines in soft agar. The upper panels show an assay in soft agar; 
the lower panels show the colony size under a × 100 magnification of 
the same wells after 3 weeks in culture. Three independent experiments 
yielded similar results. (b) Bar graph summarizing the results of three 
independent experiments in soft agar. (c) CCN6 inhibition induced an 
increase in phosphorylation of insulin-like growth factor-1 receptor 
(IGF-1R) and insulin receptor substrate-1 (IRS-1). C1 and C2 are two 
stable CCN6 deficient clones.Breast Cancer Research    Vol 7 No 6    Zhang et al.
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Cells were resuspended in 2 M HCl for 20 minutes at room
temperature. After centrifugation, the cell pellets were resus-
pended in borax (pH 8.5) to neutralize any residual acid. After
brief centrifugation the pellets were washed in 1 ml PBS and
resuspended for 1 hour in fluorescein isothiocyanate-labeled
anti-BrdU antibody (catalogue no. 347583; Becton Dickinson
San Jose, CA, USA) in the dark. Cells were washed in PBS,
resuspended in PBS containing propidium iodide, and ana-
lyzed for propidium iodide and BrdU staining on a Becton-
Dickinson flow cytometer with the use of Cellquest software.
The experiment was performed three times independently.
Results
Expression of CCN6 in immortalized human mammary 
epithelial cells
A CCN6-specific receptor has not yet been cloned; blockade
of the receptor is therefore not yet feasible as a means of inhib-
iting CCN6 function. Thus, to investigate the role of CCN6 in
the mammary epithelium and in breast tumorigenesis, HME
cells were treated with a CCN6 hairpin siRNA. siRNAs silence
gene expression in a sequence-specific post-translational
way; they therefore constitute a useful strategy for identifying
gene function [29].
The expression of CCN6 transcript and protein in HME con-
trols and HME cells stably transfected with CCN6 siRNA were
studied by RT-PCR and Western immunoblotting, respectively
(Fig. 1a). For subsequent experiments, two clones with CCN6
protein downregulation were selected to study the functional
consequences of CCN6 inhibition. The hairpin inhibition of
CCN6 protein levels was stable and remained stable 5 months
after transfection, as tested by Western blotting.
CCN6 inhibition is a potent inducer of EMT and triggers 
motile and invasive properties on mammary epithelial 
cells
While the parental HME cells were compact, thick, and ovoid,
with rare extended processes, CCN6 inhibition led to cells
that were thin, spreading, with stellate shape and numerous
cytoplasmic extended processes reminiscent of an epithelial
to mesenchymal transition (EMT) (Fig 1b). Consistently,
CCN6-deficient cells had loss of the epithelial markers E-cad-
herin and cytokeratin, whereas they exhibited increased vimen-
tin protein, a characteristic marker for mensenchymal cells
(Fig. 1c,d and 1e).
Because E-cadherin is crucial for epithelial cell-cell adhesion
and its downregulation has been shown to enhance cellular
motility and invasion, we tracked the movement of CCN6-defi-
cient cells and their ability to invade a basement membrane. As
shown in Fig. 2, CCN6 deficient cells were much more motile
and invasive in vitro than the controls.
CCN6 inhibition promotes anchorage-independent 
growth, increases IGF-1R phosphorylation and 
potentiates the mitogenic effects of IGF-1
Stable inhibition of CCN6 by hairpin siRNA strongly promoted
the growth of HME cells in soft agar (Fig. 3). CCN6-deficient
cells were able to form colonies in medium supplemented with
only 2.5% FBS, whereas HME control cells did not signifi-
cantly form colonies under these conditions. CCN6-deficient
cells formed about 10-fold more colonies than the control cells
after 21 days. Furthermore, the colonies formed by the CCN6-
deficient cells were much larger than the colonies formed by
the control cells.
Our observation of the ability of CCN6-deficient cells to form
colonies in soft agar in the presence of limiting serum sug-
gested that these lines might have increased activation of
growth receptor tyrosine kinase signaling pathways. This is a
well-known mechanism for transformation that allows the cells
to grow in the absence, or with minimal amounts, of growth
factors [30,31]. Because CCN6 contains an IGFBP motif and
once secreted it is able to modulate IGF signaling pathways
[27], it was logical to begin our analysis by investigating
whether inhibition of CCN6 might directly or indirectly induce
the activation of IGF-1R. Stable CCN6 inhibition by hairpin
siRNA led to an increase in the phosphorylation of IGF-1R and
IRS-1 (Fig. 3c).
Next, we assayed CCN6-deficient cells and controls for their
growth ability in serum free medium and in the presence of
Figure 4
CCN6 inhibition increases the growth of human mammary epithelial  cells in response to insulin-like growth factor-1 (IGF-1) CCN6 inhibition increases the growth of human mammary epithelial 
cells in response to insulin-like growth factor-1 (IGF-1). Cells were 
serum starved for 24 hours, and subsequently stimulated with 25 ng/ml 
of IGF-1. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium 
bromide) reagents were added 24 hours later and the plate was read at 
a wavelength of 595 nm. Results are expressed as means ± SD for 
three independent experiments. Asterisks indicate statistical signifi-
cance (t test); p < 0.005 for short interfering RNA (siRNA)/CCN6 after 
treatment with IGF-1 compared with serum free medium (SFM). C1 and 
C2 are two stable CCN6 deficient clones.Available online http://breast-cancer-research.com/content/7/6/R1080
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IGF-1 in the condition media. In the complete absence of
serum, CCN6-deficient cells were able to survive and were
metabolically active when compared to controls (Fig. 4). Upon
addition of IGF-1 we observed that inhibition of CCN6
enhanced the growth effects of IGF-1. Inhibition of CCN6
stimulated the growth of HME cells in serum free medium,
however, when 25 ng of IGF-1 was added, we noted a 2.5-fold
increase in cell growth, which did not increase significantly
with increasing concentrations of recombinant IGF-1 in the
medium.
While IGF-1 stimulation did not affect the proliferative activity
of the control cells, CCN6-deficient cells exhibited a signifi-
cant increase in the S-phase fraction (Fig. 5). Taken together
these data support the hypothesis that loss of CCN6 in HME
cells results in loss of a growth regulatory mechanism which
enhances the proliferative and growth response to IGF-1.
Discussion
In this study we characterize the function of CCN6, a recently
identified gene that is lost in inflammatory breast cancer, the
most lethal form of breast cancer [6,25]. Here we show that
inhibition of CCN6 expression induces the EMT of mammary
epithelial cells and results in a highly motile and invasive phe-
notype. CCN6-deficient cells acquire anchorage-independent
growth abilities and exhibit increased growth and proliferative
response to IGF-1 through enhanced IGF-1R signaling.
To characterize the function of CCN6 in the breast epithelium,
we first analyzed the phenotypic effects of stable inhibition of
CCN6 expression by hairpin siRNA. Inhibition of CCN6 pro-
foundly altered the phenotype of human mammary epithelial
cells, leading to the acquisition of features of EMT. EMT
involves the phenotypic alteration of epithelial cells to fibrob-
lastoid, spindle, migratory, and more malignant cells, which
show a mesenchymal gene expression program [32,33], and
represents an important in vitro correlate of tumor progression
[32,33]. Several proteins have been implicated in this process,
which involves a dominant transcriptional repression that
leads to a downregulation of E-cadherin expression and an
increase in the expression of mesenchymal markers. The
detailed mechanisms of EMT in breast epithelial cells remain
elusive.
Figure 5
CCN6 inhibition enhances the proliferative effects of insulin-like growth factor-1 (IGF-1) on mammary epithelial cells CCN6 inhibition enhances the proliferative effects of insulin-like growth factor-1 (IGF-1) on mammary epithelial cells. The bar graph shows that 
CCN6-deficient cells exhibited a significant increase in bromodeoxyuridine (BrdU) incorporation in response to treatment with IGF-1 (t test, p < 0.03 
for both clones). The human mammary epithelial (HME) control cells did not exhibit differences in the S-phase fraction after the addition of IGF-1. 
The experiment was performed three times independently. Results are expressed as means ± SD for three independent experiments. C1 and C2 are 
two stable CCN6 deficient clones.Breast Cancer Research    Vol 7 No 6    Zhang et al.
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On the basis of our studies, inhibition of CCN6 results in a
morphologic change towards a mesenchymal phenotype,
which is accompanied by a marked downregulation of E-cad-
herin and cytokeratin, and an increase in vimentin, a mesen-
chymal marker. Functionally, CCN6 inhibition led to a
pronounced increase in cell motility and invasion. The mecha-
nism of E-cadherin downregulation brought about by the loss
of CCN6 is intriguing. E-cadherin transcript expression was
also inhibited in CCN6-deficient cells, suggesting that this
effect is probably exerted at the transcriptional level, by epige-
netic mechanisms such as hypermethylation and transcrip-
tional silencing. These results were also obtained when CCN6
was knocked down in MCF10A cells (data not shown). It is
possible that the loss of CCN6 might lead to increased meth-
ylation of the E-cadherin promoter, which has been shown to
be correlated with a loss of E-cadherin expression in breast
cancer cell lines and primary invasive ductal and lobular
carcinomas of the breast [34,35]. It is also possible that
CCN6 loss results in transcriptional silencing of E-cadherin,
perhaps by the induction of transcriptional repressors, such as
Snail [36,37] and SIP1/ZEB2 [36,37], known to inactivate the
E-cadherin promoter. Supporting evidence has recently been
reported by Sen and colleagues [38] showing that CCN6 is
able to activate the SOX transcription factors by a similar
mechanism.
CCN6 inhibition led to the acquisition of anchorage-independ-
ent growth abilities even under extremely low serum condi-
tions. We therefore reasoned that loss of CCN6 might impair
a central growth regulatory mechanism, rendering the cells
more sensitive to the effect of even minimal amounts of growth
factors such as EGF and IGF. Although CCN6 inhibition had
no effect on the phosphorylation of the EGF receptor (data not
shown), it markedly enhanced the growth effects of IGF-1, a
potent mitogen for breast epithelial cells [39]. CCN6 inhibition
led to an increase in the phosphorylation of IGF-1R and its
main downstream target molecule IRS-1. This was coupled
with an increase in the metabolic and proliferative activities of
mammary epithelial cells. These data support a role for CCN6
a modulator of the growth effects of IGF-1 on the breast epi-
thelium, and may have clinical implications, as CCN6 loss may
mark an epithelium at increased risk of malignant transforma-
tion and might constitute a target for breast cancer prevention.
The IGF family of growth factors is crucial in the development
and progression of breast cancer. Studies in vitro and in vivo
have shown that IGFs promote the proliferation, survival, and
metastatic ability of cancer cells [40-43]. The role of IGF-1R in
promoting the proliferation of breast cancer cells is well estab-
lished [39,44,45]. A role for IGF-1R in breast cancer metas-
tases has been shown recently [40]. Compelling
epidemiological and clinical data show that high concentra-
tions of IGF-1 in serum are associated with increased mammo-
graphic density (one of the strongest predictors of breast
cancer risk), and also reliably predict increased breast cancer
risk specifically in premenopausal women [46]. High expres-
sion of IGF-1R has been demonstrated in most primary human
breast cancers when compared with normal or benign breast
tissue, and hyperactivation of IGF-1R in breast cancer has
been linked with increased radioresistance and cancer recur-
rence at the primary site [39,44,45]. High levels of IRS-1, a
major signaling molecule downstream of the IGF-1R, are cor-
related with tumor size and shorter disease-free survival in
estrogen receptor-positive breast cancer patients [47,48].
The effect of CCN6 inhibition on the phosphorylation of the
IGF-1R and IRS-1 is consistent with a growth regulatory effect
on the mammary epithelium. The relationship between the IGF
family and CCN6 emerges from our previous investigations as
well as from another laboratory [14,27,38]. CCN6-rich
medium induces a decrease in IGF-1-stimulated IGF-1R phos-
phorylation in breast cancer cells, and then results in an inhibi-
tion of cellular proliferation [27]. In another system, Sen and
colleagues [38] reported that anti-IGF-1 neutralizing antibody
partly blocks the CCN6-mediated upregulation of COL2A1
mRNA in immortalized chondrocyte cell lines. In view of these
data, we postulate that CCN6 may modulate the availability of
IGF-1 to the IGF-1R, conceivably by binding and sequestering
IGF-1, and/or by interfering with other regulators of the IGF
signaling pathway.
Conclusion
We propose a model whereby CCN6 serves as an important
growth regulatory protein of the mammary epithelium and con-
trols the cellular responses to the growth stimulatory effects of
IGF-1. Loss of CCN6 expression alters the phenotype of the
breast epithelium and promotes motility and invasion. The
CCN6-deficient cells are extremely sensitive to the growth
stimulatory effects of IGF-1. The uncontrolled growth may in
turn predispose to neoplasia. It is possible that pharmacologi-
cal restoration of the CCN6 autocrine regulatory loop could be
targeted to prevent malignant transformation of mammary epi-
thelial cells.
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